108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
血栓性静脉炎样血管病的临床特征及病程：一项 10 年回顾性分析
Authors Gao Y, Li Y , Mairepati D, Wu H, Liu J, Han J, Zhou H
Received 8 July 2025
Accepted for publication 22 September 2025
Published 30 September 2025 Volume 2025:18 Pages 2531—2540
DOI https://doi.org/10.2147/CCID.S549839
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Jeffrey Weinberg
Yali Gao,1 Yaling Li,2 Dilixiati Mairepati,1,3 Haijian Wu,4 Junfeng Liu,5 Jiande Han,1 Hui Zhou1
1Department of Dermatology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, People’s Republic of China; 2Department of Dermatology, Institute of Dermatology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong, 518036, People’s Republic of China; 3Burn Plastic Wound Repair Surgery, The Eighth Affiliated Hospital of Xinjiang Medical University (Xinjiang Uygur Autonomous Region Burn Hospital), Urumqi, Xinjiang Uygur Autonomous Region, 830011, People’s Republic of China; 4Xinwei Town Central Health Center, Huizhou, Guangdong, 516223, People’s Republic of China; 5Department of Medical Records, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, People’s Republic of China
Correspondence: Jiande Han; Hui Zhou, Email hanjd@mail.sysu.edu.cn; zhouhui5@mail.sysu.edu.cn
Objective: Livedoid vasculopathy (LV) is a rare, chronic, recurrent thrombo-occlusive cutaneous disorder, which is also known as atrophie blanche (AB). Its characteristic clinical manifestations include livedo racemosa, painful ulcerations, and white atrophic scars predominantly on the lower extremities. This study aimed to investigate the clinical appearance, histological features and laboratory test results, treatment strategies, and clinical outcomes of LV to provide evidence for clinical diagnosis and management.
Methods: We conducted a retrospective analysis of clinical data from 69 LV patients diagnosed in the First Affiliated Hospital of Sun Yat-sen University between January 2014 and December 2024. Data encompassed demographic characteristics, clinical manifestations, histopathological features, laboratory investigations, treatment regimens, and follow-up results. Treatment efficacy was assessed based on ulcer healing time and patient-reported symptom improvement.
Results: The median age was 31 years (range: 11– 85 years), with females constituting 69.6% (48/69). Only 5 patients (7.3%, 5/69) received an initial diagnosis of LV. The predominant clinical presentations were recurrent painful ulcerations (89.9%, 62/69), white atrophic scars (82.6%, 57/69), purpura (84.1%, 58/69), livedo racemosa (75.4%, 52/69) and local pain (85.5%, 59/69) on the lower extremities. Treatment modalities primarily included anticoagulant therapy, antiplatelet therapy, corticosteroids, lipid-lowering therapy, immunosuppressive agents, traditional Chinese medicine and physical therapy modalities.
Conclusion: LV predominantly affects young and middle-aged females. Combination therapy with anticoagulant, antiplatelet and corticosteroids significantly contributes to ulcer healing and rapid pain relief. Long-term follow-up is necessary to monitor for potential progression to systemic diseases. As a single-center retrospective study, these findings warrant further validation through multicenter prospective research.
Keywords: livedoid vasculopathy, anticoagulant therapy, antiplatelet therapy, immunomodulatory agents
1Department of Dermatology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, People’s Republic of China; 2Department of Dermatology, Institute of Dermatology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong, 518036, People’s Republic of China; 3Burn Plastic Wound Repair Surgery, The Eighth Affiliated Hospital of Xinjiang Medical University (Xinjiang Uygur Autonomous Region Burn Hospital), Urumqi, Xinjiang Uygur Autonomous Region, 830011, People’s Republic of China; 4Xinwei Town Central Health Center, Huizhou, Guangdong, 516223, People’s Republic of China; 5Department of Medical Records, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, People’s Republic of China
Correspondence: Jiande Han; Hui Zhou, Email hanjd@mail.sysu.edu.cn; zhouhui5@mail.sysu.edu.cn
Objective: Livedoid vasculopathy (LV) is a rare, chronic, recurrent thrombo-occlusive cutaneous disorder, which is also known as atrophie blanche (AB). Its characteristic clinical manifestations include livedo racemosa, painful ulcerations, and white atrophic scars predominantly on the lower extremities. This study aimed to investigate the clinical appearance, histological features and laboratory test results, treatment strategies, and clinical outcomes of LV to provide evidence for clinical diagnosis and management.
Methods: We conducted a retrospective analysis of clinical data from 69 LV patients diagnosed in the First Affiliated Hospital of Sun Yat-sen University between January 2014 and December 2024. Data encompassed demographic characteristics, clinical manifestations, histopathological features, laboratory investigations, treatment regimens, and follow-up results. Treatment efficacy was assessed based on ulcer healing time and patient-reported symptom improvement.
Results: The median age was 31 years (range: 11– 85 years), with females constituting 69.6% (48/69). Only 5 patients (7.3%, 5/69) received an initial diagnosis of LV. The predominant clinical presentations were recurrent painful ulcerations (89.9%, 62/69), white atrophic scars (82.6%, 57/69), purpura (84.1%, 58/69), livedo racemosa (75.4%, 52/69) and local pain (85.5%, 59/69) on the lower extremities. Treatment modalities primarily included anticoagulant therapy, antiplatelet therapy, corticosteroids, lipid-lowering therapy, immunosuppressive agents, traditional Chinese medicine and physical therapy modalities.
Conclusion: LV predominantly affects young and middle-aged females. Combination therapy with anticoagulant, antiplatelet and corticosteroids significantly contributes to ulcer healing and rapid pain relief. Long-term follow-up is necessary to monitor for potential progression to systemic diseases. As a single-center retrospective study, these findings warrant further validation through multicenter prospective research.
Keywords: livedoid vasculopathy, anticoagulant therapy, antiplatelet therapy, immunomodulatory agents